Lilly Reports Q2 2024 Financial Results, Raises Full-Year Revenue Guidance by $3 Billion - Investors | Eli Lilly and Company
- Lilly Reports Q2 2024 Financial Results, Raises Full-Year Revenue Guidance by $3 Billion Investors | Eli Lilly and Company
- Eli Lilly stock surges on Q2 earnings beat, revenue outlook Yahoo Finance
- Eli Lilly blows past estimates, hikes guidance as Zepbound, Mounjaro sales soar CNBC
- Eli Lilly Lifts 2024 Sales Outlook as Zepbound Demand Drives Quarter Bloomberg